In today's ACT Brief, we examine how AI surfaces design flaws before enrollment, why site training readiness depends on learning science, and the priorities defining next-generation weight-loss therapies.
News|Podcasts|September 9, 2026
ACT Brief: RBQM Multi-Functional Buy-In and E6(R3), Site Payment Performance and Cash Runway, and Inhaled Therapy for Cystic Fibrosis
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine how regulatory guidance and financial evidence enable RBQM adoption, why site payment performance remains a competitive differentiator, and a collaboration advancing an inhaled approach to cystic fibrosis.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In
part four and final segment of the interview , Sylviane de Viron of CluePoints and Abigail Dirks of Tufts CSDD explained how ICH E6(R3) and new empirical evidence of RBQM's net financial impact give sponsors the tools they need to build the multi-functional buy-in required for successful adoption. RBQM only delivers full value when it replaces, not supplements, traditional monitoring, making governance and operating model change prerequisites to deployment. - In a
new Q&A , Patrick Mizer, chief technology officer at Ledger Run, discussed how payment reliability has become a competitive differentiator in site selection as high-performing sites gain more study opportunities than they can support. With 80% of sites operating on six months or less of cash, improving payment infrastructure is no longer optional, and agentic AI is proving effective at removing manual invoice processing that consumed 60% of customer time historically. Aptar Pharma and Aceso Therapeutics partnered to advance a gene therapy candidate designed to target the underlying disease mechanisms of cystic fibrosis affecting approximately 100,000 people worldwide. Nanopharm, Aptar Pharma's inhalation development services business, will lead formulation development and device assessment, applying inhalation science expertise to an early-stage asset ahead of clinical evaluation.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment.
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
Trending on Applied Clinical Trials Online
1
Using AI to Design Better Trials Before the First Patient Enrolls: Q&A with Claire Riches, Citeline
2
ACT Brief: FDA Transparency Roadmap, Radiopharmaceutical Trial Operations, and AI-Powered Enrollment Prediction
3
ACT Brief: AI and Protocol Design, Site Training Readiness, and GLP-1 Unmet Needs
4
FDA Releases Transparency Roadmap Outlining Disclosure Priorities Across Drug Development and Regulatory Review
5